Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings

Bone Marrow Transplant. 1990 Jul:6 Suppl 1:98-102.

Authors

R Foa¹, G Meloni, S Tosti, A Novarino, S Fenu, A Guarini, S Cardona, A Gillio Tos, F Gavosto, F Mandelli

Affiliation

¹ Dipartimento di Scienze Biomediche e Oncologia Umana, University of Torino, Italy.

PMID: 2202476

No abstract available

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Bone Marrow / immunology
Bone Marrow / pathology
Clinical Trials as Topic
Humans
Immunotherapy
Interleukin-2 / adverse effects
Interleukin-2 / therapeutic use*
Killer Cells, Lymphokine-Activated / immunology
Leukemia, Myeloid, Acute / immunology
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Thrombocytopenia / etiology

Substances

Interleukin-2